VTYX Stockholders are Encouraged to Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Ventyx Biosciences, Inc. Class Action
Ventyx Biosciences, Inc. (VTYX)
Company Research
Source: GlobeNewswire
SAN DIEGO, April 17, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all those who purchased or otherwise acquired Ventyx Biosciences, Inc. (NASDAQ: VTYX) (1) pursuant to the Offering Documents issued in connection with the Company's October 2021 initial public offering (“IPO”) or (2) Ventyx securities between October 21, 2021 and November 6, 2023. Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases. The Company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. In 2022, Ventyx initiated a Phase 2 clinical trial of VTX958 for the treatment of moderate to severe plaque psoriasis (the “Phase 2 SERENITY Trial”). For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegat
Show less
Read more
Impact Snapshot
Event Time:
VTYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTYX alerts
High impacting Ventyx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
VTYX
News
- What Makes Ventyx Biosciences (VTYX) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- April 30, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTYXAccesswire
- VTYX DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYXPR Newswire
- Class Action Filed Against Ventyx Biosciences, Inc. (VTYX) Seeking Recovery for Investors - Contact Levi & KorsinskyAccesswire
- Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreAccesswire
VTYX
Earnings
- 11/9/23 - Miss
VTYX
Sec Filings
- 4/30/24 - Form EFFECT
- 4/29/24 - Form EFFECT
- 4/25/24 - Form ARS
- VTYX's page on the SEC website